The White House actively lobbies pharmaceutical companies. The aim is to gain their support for the bill on medicine prices. These efforts take place in the form of private meetings. The initiative is part of a broader effort by the administration to focus on the affordability of medicines in the pre-election period. The specific details of the bill and the reactions of pharmaceutical companies were not specified in this brief.